Inventor · disambiguated record
Cecile Bonnafous
Also filed as: BONNAFOUS CECILE · BONNAFOUS CÉCILE
9 granted patents·7 pending applications·21 citations·filing 2007–2024
84Inventor score
Top patents by PatentIndex Score
16 records- 0190US11078275B2Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2019·Granted Aug 3, 2021·3 cites·12 claims
- 0290US10174112B2Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2017·Granted Jan 8, 2019·9 cites·12 claims
- 0387US2025092130A1Compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphomaINNATE PHARMA·Filed 2024·Application pending·0 cites
- 0482US10344087B2Treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2014·Granted Jul 9, 2019·3 cites·7 claims
- 0582US2024425586A1Treatment of peripheral t cell lymphomaINNATE PHARMA·Filed 2024·Application pending·0 cites
- 0679US10736963B2Methods for detecting tissue infiltrating NK cellsINNATE PHARMA·Filed 2016·Granted Aug 11, 2020·2 cites·5 claims
- 0777US10577416B2Mica binding agentsINNATE PHARMA SA·Filed 2013·Granted Mar 3, 2020·3 cites·3 claims
- 0876US12084498B2Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2021·Granted Sep 10, 2024·0 cites·13 claims
- 0971US11999784B2Treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2019·Granted Jun 4, 2024·0 cites·1 claims
- 1067US10494433B2Combination of anti-KIR and anti-CS1 antibodies to treat multiple myelomaBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Dec 3, 2019·1 cites·14 claims
- 1160US2016002345A1A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphomaINNATE PHARMA·Filed 2014·Application pending·0 cites
- 1258US2020299380A1Mica binding agentsINNATE PHARMA·Filed 2020·Application pending·0 cites
- 1351US2024117042A1Immunohistochemistry methods and kir3dl2-specific reagentsINNATE PHARMA·Filed 2022·Application pending·0 cites
- 1444US9944712B2TLR3 binding agentsINNATE PHARMA·Filed 2013·Granted Apr 17, 2018·0 cites·28 claims
- 1544US2010029674A1Methods of Using Phosphoantigen for the Treatment of CancerINNATE PHARMA SA·Filed 2007·Application pending·0 cites
- 1637US2014065154A1Tlr3 binding agentsGAUTHIER LAURENT·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Cecile Bonnafous files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →